Bright Minds Biosciences

Bright Minds launches NOVA—a Phase 2 study of BMB-101 in Prader-Willi Syndrome. A new era in neuro-obesity research begins. ✨ $DRUG

New preclinical data: BMB-201 outperformed sumatriptan in a validated vascular headache model, showing robust efficacy across sexes and multiple timepoints. $DRUG

Big news ! 💥We've teamed up with @BrightMindsBio to bring our real-time seizure detection tech to their phase 2 trial for drug-resistant #epilepsy. Making invisible seizures visible → right from home 📱🧠💡 #digitalhealth #EEG #clinicaltrials 🔗 hubs.la/Q03tk5xR0

Today is Jeavons Syndrome Awareness Day. A disorder near and dear to our hearts.

Full press release below 👇 globenewswire.com/news-release/2…

We are pleased to announce closing of a $35m Offering including participation from Cormorant Asset Management, RA Capital Management, Perceptive Advisors, Janus Henderson Investors, Vivo Capital, Acuta Capital Partners, Schonfeld Strategic Advisors + other healthcare investors.

🧠 Excited to present our latest research poster at the 2024 SnF conference! 🧠 In collaboration with the NIH Epilepsy Therapy Screening Program (ETSP), we explored BMB-101 and JJ42, highly selective 5-HT2C agonists with promising results for epileptic disorders.

Bright Minds Biosciences will participate in the NIH satellite forum on October 7. NINDS efforts to support innovative research are truly remarkable. Today we will present the data obtained in collaboration with PSPP (Pain) and ETSP (Epilepsy) programs.

Bright Minds participates in the ongoing Neuroscience 2024 annual meeting, organized by the SfN in Chicago and presented a poster about the development of BMB-202. Title: Novel 5-HT2A-selective agonists with well-characterized PK profile and short duration of action. #sfn2024

Join us tomorrow at 10:00 a.m. for an exclusive KOL event discussing BMB 101 for epilepsy treatment, including the Phase 2 BREAKTHROUGH trial. Don't miss the chance to hear from leading experts. Register now: brightmindsbio.com/bright-minds-b… #Epilepsy $DRUG #BMB101

BMB-101 (@brightmindsbio), a 5-HT2C receptor agonist, will be tested in a cohort of 20 adults aged 18 to 65 with absence epilepsy or a developmental encephalopathy for an 8-to-12-week treatment period. More on the newly announced BREAKTHROUGH trial: neurologylive.com/view/newly-ini…

@Pharmechanic @zenbrainest @Pharmechanic Take a look at this paper for an example of the tolerance phenomenon: He Y, et al. Barbadin Potentiates Long-Term Effects of Lorcaserin on POMC Neurons and Weight Loss. J Neurosci. 2021 Jun 30:41(26):5734-5746. doi: 10.1523/JNEUROSCI.3210-20.2021

@zenbrainest @brightmindsbio Cool! Thanks Bryan. Is there in vitro pharmacology published on this? Is the idea that it will be better for chronic dosing because the reduced arrestin recruitment will minimize desensitization? (I’m looking for an example of this for a presentation.)

The very first G protein biased, subtype-selective serotonergic agonist now in Phase II! @brightmindsbio

@zenbrainest @markfrommacq @Pharmechanic Phase 1 qEEG showed a robust anti-epileptic signature and preclinical epilepsy models showed strong efficacy.

@markfrommacq @Pharmechanic @brightmindsbio From the perspective of a GABA-ergic neuron it could be optimal but who knows until this trial.

Today we announce the BREAKTHROUGH study: a phase 2 trial on BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy. More details at the Press Release link: brightmindsbio.com/bright-minds-b…

A new preclinical study shows promising results for 5-HT2AR agonists, with no hallucinogenic effects, in alleviating neuropathic and visceral pains. sciencedirect.com/science/articl…

A pre-print article on psilocybin treatment in an animal model of obsessive compulsive disorder (OCD) shows the possible long-term benefit of such compound in OCD patients. biorxiv.org/content/10.110…

A new study revealed how psilocybin affects human brain cells and neuroplasticity in human induced pluripotent stem cells (iPSC)-derived cortical neurons: brain-derived neurotrophic factor (BDNF), neuron growth and connections were found increased researchsquare.com/article/rs-424…

A new article published on Nature compared the effects of psychedelic mushroom extract vs. synthesized psilocybin on mouse brain. #citeas" target="_blank" rel="nofollow noopener">nature.com/articles/s4138…